Management of Initial and Recurrent C. difficile Infections
  • CME

Gain expert insights on the latest data and guidance for managing challenging C. difficile infections in this case-focused, CME-certified Interactive Virtual Presentation.
Ciarán P. Kelly, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: November 21, 2018 Expiration: November 20, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe serologic and fecal tests for detection of toxigenic C difficile and their indications for use
  • List recommended antimicrobial regimens that have the highest levels of efficacy in treating primary CDI
  • Describe recent advances in the prevention of recurrent CDI in high risk patients and their place in therapy

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Ciarán P. Kelly, MD

Professor of Medicine
Department of Medicine
Harvard Medical School
Attending Physician
Division of Gastroenterology
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Ciarán P. Kelly, MD, has disclosed that he has received consulting fees from Artugen, Merck, and Vedanta, fees for non-CME/CE services from Biocodex, and funds for research support from Institut Merieux.


Ryan P. Topping, PhD

Managing Editor

Ryan Topping, PhD, has no significant financial relationships to disclose.
Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no significant financial relationships to disclose.
Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, has disclosed that she has received fees for non-CME activities from Merck and Eli Lilly.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with Clostridium difficile infection.


The goal of this activity is to improve participants’ clinical competence in managing patients with Clostridium difficile infection.

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 21, 2018, through November 20, 2019:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Dr. Stephen Harrison summarizes new and emerging NASH targets and treatments: ASK1, FXR, PPAR, CCCR2/5, and more

Kenneth Cusi, MD, FACP, FACE
Program Director
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Released: January 18, 2019

Expert commentary from Dr. Jeffrey Crawford on the tally of biosimilars available for cancer care and how their use may affect patient management.

Jeffrey Crawford, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 18, 2019 Expiration: January 17, 2020

Dr. Stephen Harrison and Dr. Juan Frias summarize new and emerging NASH targets and treatments: ASK1, FXR, PPAR, CCCR2/5, and more

person default Juan Pablo Frias, MD, FACE Stephen A. Harrison, MD, COL (Ret.), FAASLD Released: January 18, 2019

Downloadable slides from live event at ASCO GI Cancers Symposium 2019 review future directions for pancreatic cancer with DNA damage repair mutations

Tanios Bekaii-Saab, MD, FACP Released: January 17, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?